Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PSTV

Plus Therapeutics Inc

Apr 24 • 04:00PM ET

6.60

-0.68 -9.34 %

Healthcare • Biotechnology • USA • NASD

Apr 23, 8:05 AMPlus Therapeutics starts manufacturing, tech transfer with SpectronRx to add second GMP site for REYOBIQ pivotal trial readiness

Peers: ADAP SUPN KPTI IMUX LITS PBYI CRIS RIGL SYBX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-32.09	Insider Own	0.64%	Shs Outstand	6.86M	Perf Week	3.29%
Market Cap	45.29M	Forward P/E	-	EPS next Y	-2.13	Insider Trans	83.61%	Shs Float	6.82M	Perf Month	7.36%
Enterprise Value	33.00M	PEG	-	EPS next Q	-0.85	Inst Own	14.89%	Short Float	19.77%	Perf Quarter	-2.62%
Income	-26.35M	P/S	8.69	EPS this Y	52.36%	Inst Trans	-	Short Ratio	3.44	Perf Half Y	-55.22%
Sales	5.21M	P/B	9.16	EPS next Y	38.22%	ROA	-229.51%	Short Interest	1.35M	Perf YTD	-48.47%
Book/sh	0.72	P/C	3.45	EPS next 5Y	60.26%	ROE	-	52W High	24.25 -72.78%	Perf Year	-68.67%
Cash/sh	1.91	P/FCF	-	EPS past 3/5Y	70.82% 59.95%	ROIC	-656.84%	52W Low	2.90 127.59%	Perf 3Y	-92.99%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	185.50% 76.66%	Gross Margin	91.46%	Volatility	13.24% 15.49%	Perf 5Y	-99.27%
Dividend TTM	-	EV/Sales	6.33	EPS Y/Y TTM	43.96%	Oper. Margin	-293.46%	ATR (14)	0.76	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	1.20	Sales Y/Y TTM	-10.49%	Profit Margin	-505.39%	RSI (14)	55.52	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	1.20	EPS Q/Q	93.78%	SMA20	25.07%	Beta	1.54	Target Price	45.40
Payout	-	Debt/Eq	0.20	Sales Q/Q	-3.19%	SMA50	5.50%	Rel Volume	0.58	Prev Close	7.28
Employees	28	LT Debt/Eq	0.00	Earnings	Mar 12 AMC	SMA200	-41.49%	Avg Volume	391.51K	Price	6.60
IPO	Oct 22, 2003	Option/Short	No / Yes	EPS/Sales Surpr.	-4.20% 10.63%	Trades		Volume	228,110	Change	-9.34%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-03-26	Initiated	Lake Street	Buy	$2
Sep-03-25	Upgrade	D. Boral Capital	Hold → Buy	$5
Mar-17-25	Initiated	D. Boral Capital	Buy	$9
Jan-25-21	Initiated	Ladenburg Thalmann	Buy	$8
Oct-16-20	Initiated	Maxim Group	Buy	$6

Apr-23-26 07:30AM	Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ (GlobeNewswire)
Apr-22-26 04:30PM	Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.72%
Apr-21-26 07:30AM	Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Apr-15-26 07:30AM	Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution (GlobeNewswire)
Apr-09-26 07:30AM	Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline (GlobeNewswire) +23.66%
07:30AM	Loading…
Apr-08-26 07:30AM	Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ in Pediatric Malignant Gliomas (GlobeNewswire) +8.56%
Apr-07-26 07:30AM	Plus Therapeutics Receives AMA PLA Code for CNSide CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption (GlobeNewswire) -12.31%
Apr-02-26 07:30AM	Plus Therapeutics Secures Highmark Coverage for CNSide CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives (GlobeNewswire) -8.60%
Mar-31-26 04:30PM	Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -24.23%
07:30AM	Plus Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Mar-26-26 07:30AM	Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors (GlobeNewswire)
Mar-19-26 07:30AM	Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide May Reduce Leptomeningeal Metastases Healthcare Costs by 40% (GlobeNewswire)
Mar-12-26 06:27PM	Plus: Q4 Earnings Snapshot (Associated Press Finance) -15.17%
04:15PM	Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ Clinical Program and CNSide Commercial Rollout (GlobeNewswire)
Feb-26-26 06:00PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates (Zacks) +7.67% -6.66%
07:30AM	Loading…
Feb-25-26 07:30AM	Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ (GlobeNewswire) +7.57%
Jan-22-26 07:45AM	Plus Therapeutics Provides Business Update on REYOBIQ Clinical Program and U.S. CNSide Commercialization (GlobeNewswire)
Jan-21-26 04:15PM	Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET (GlobeNewswire)
Jan-14-26 11:36AM	Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges (Benzinga) -38.23%
08:00AM	Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering (GlobeNewswire)
Jan-08-26 07:30AM	Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ for Leptomeningeal Metastases (GlobeNewswire)
Dec-11-25 07:30AM	Plus Therapeutics Expands CNSide Assay Platform to State of California (GlobeNewswire) +7.11%
Dec-09-25 07:30AM	Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants (GlobeNewswire) +6.35%
Dec-04-25 07:30AM	Plus Therapeutics Highlights Three REYOBIQ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting (GlobeNewswire) +9.75%
Dec-01-25 07:30AM	Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-24-25 07:30AM	Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ in Leptomeningeal Metastases (GlobeNewswire) +7.98%
Nov-20-25 07:30AM	Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer (GlobeNewswire)
Nov-17-25 07:30AM	Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement (GlobeNewswire) -7.08%
Nov-06-25 07:30AM	Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0 (GlobeNewswire) -5.71%
Oct-30-25 06:45PM	Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
05:41PM	Loading…
05:41PM	Plus: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-29-25 07:40AM	United Therapeutics (UTHR) Beats Q3 Earnings Estimates (Zacks) -7.39%
Oct-21-25 07:30AM	Plus Therapeutics Updates on CNSide Diagnostic Platform Launch (GlobeNewswire) +6.94%
Oct-15-25 08:45AM	Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge (PR Newswire)
06:19AM	Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics (Zacks)
Oct-14-25 10:57AM	5 Small Drug Stocks to Buy as the Industry Shows Some Recovery (Zacks)
Sep-26-25 08:07AM	Plus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United Healthcare (Insider Monkey) +9.61%
Sep-25-25 07:31AM	Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare For CNS Cancer Diagnostic Kit (Benzinga) +39.29%
07:30AM	Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer (GlobeNewswire)
Sep-22-25 07:30AM	Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT (GlobeNewswire)
Sep-18-25 07:30AM	Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide Diagnostics Clinical Laboratory (GlobeNewswire)
Sep-02-25 04:15PM	Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) -6.27% +7.60%
Aug-26-25 07:30AM	Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria (GlobeNewswire)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -14.62%
07:30AM	Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ in Leptomeningeal Metastases (GlobeNewswire)
Aug-15-25 07:30AM	Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements (GlobeNewswire) +15.81%
Aug-14-25 05:30PM	Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -5.61%
04:26PM	Plus: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights (GlobeNewswire)
07:30AM	Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference (GlobeNewswire)
Aug-13-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -21.40%
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-06-25 05:35PM	Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +15.47%
Aug-05-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -10.97%
08:25AM	Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-31-25 07:30AM	Plus Therapeutics Provides US Launch Update for its CNSide Diagnostic (GlobeNewswire) +5.62%
Jul-24-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +21.73%
Jul-23-25 07:30AM	Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT (GlobeNewswire) +15.29%
Jul-22-25 07:11AM	Leptomeningeal Metastases Market Research Report 2025-2035 \| Competitive Analysis of Plus Therapeutics, AstraZeneca, AngioChem, and Y-mAbs Therapeutics (GlobeNewswire) +10.68%
Jul-15-25 07:30AM	Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ in Patients with Leptomeningeal Metastases (GlobeNewswire) -5.74%
Jul-10-25 07:30AM	Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference (GlobeNewswire)
Jul-08-25 07:30AM	Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ in Leptomeningeal Metastases (GlobeNewswire) +10.88%
Jun-30-25 07:30AM	Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ in Leptomeningeal Metastases (GlobeNewswire) +10.38%
Jun-26-25 08:26AM	FDA approves Plus Therapeutics' Reyobiq for paediatric brain cancer (Pharmaceutical Business Review) +16.38%
07:30AM	Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary (GlobeNewswire)
Jun-25-25 04:15PM	Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET (GlobeNewswire) +68.45%
07:30AM	Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer (GlobeNewswire)
Jun-24-25 07:30AM	Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing (GlobeNewswire)
Jun-19-25 12:00PM	Plus (PSTV) Upgraded to Buy: Here's Why (Zacks)
May-30-25 05:25PM	Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +28.16%
05:20PM	Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights (GlobeNewswire)
May-29-25 05:30PM	The Cooper Companies (COO) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
May-23-25 04:15PM	Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q (GlobeNewswire)
May-15-25 05:40PM	Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -17.09%
May-14-25 10:00AM	Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) -24.05%
08:15AM	Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Plus Therapeutics' REYOBIQ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) (GlobeNewswire)
May-12-25 05:10PM	Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +8.74%
May-08-25 08:00AM	Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +10.01%
07:00AM	Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference (GlobeNewswire)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks) -14.32%
Apr-23-25 09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks) +24.97%
08:00AM	Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors (GlobeNewswire)
Apr-15-25 07:30AM	Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (GlobeNewswire)
Apr-01-25 12:00PM	Plus (PSTV) Upgraded to Buy: Here's What You Should Know (Zacks) +7.36%
Mar-28-25 01:12PM	Q4 2024 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -23.68%
03:04AM	Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Mar-27-25 07:42PM	Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript (SeekingAlpha)
05:35PM	Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-21-25 12:17PM	PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug (Zacks) -14.49%
06:34AM	Why Plus Therapeutics Inc. (PSTV) Surged On Thursday? (InsiderMonkey)
Mar-20-25 07:30AM	Plus Therapeutics Introduces REYOBIQ , FDA-Accepted Proprietary Name for Lead Drug Candidate (GlobeNewswire) +170.06%
Mar-19-25 07:30AM	Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025 (GlobeNewswire) -8.44%
Mar-11-25 11:00AM	D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement (ACCESSWIRE) +12.60%
Mar-10-25 07:30AM	Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement (GlobeNewswire) -19.11%
Mar-07-25 01:49PM	Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday (Insider Monkey) +9.03%
07:33AM	FDA ODD given to Plus Therapeutics injectable radiotherapy (Pharmaceutical Technology)

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	Apr 01 '26	Option Exercise	0.00	67,452	0	173,913	Apr 01 07:30 AM
HEDRICK MARC H	Chief Executive Officer	Apr 01 '26	Option Exercise	0.00	159,681	0	499,468	Apr 01 07:30 AM
HEDRICK MARC H	Chief Executive Officer	Jan 01 '26	Option Exercise	0.00	159,681	0	339,787	Jan 02 04:30 PM
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	Jan 01 '26	Option Exercise	0.00	38,323	0	106,461	Jan 02 04:30 PM
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	Nov 04 '25	Buy	0.51	20,000	10,200	68,138	Nov 05 08:30 AM
HEDRICK MARC H	Chief Executive Officer	Oct 01 '25	Option Exercise	0.00	159,681	0	180,106	Oct 03 04:30 PM
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	Oct 01 '25	Option Exercise	0.00	38,323	0	48,138	Oct 03 04:30 PM
Lenk Robert P	Director	Aug 22 '25	Buy	0.49	110,000	53,779	139,327	Aug 25 07:30 AM
Petersen Greg	Director	May 15 '25	Proposed Sale	0.55	36,666	20,276		May 07 11:59 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PSTV

Plus Therapeutics Inc

Upgrade your Finviz experience